KIT and gastrointestinal stromal tumor: Approximately 90% of patients with KIT-mutant GIST who had disease progression on imatinib harbor newly acquired secondary KIT mutations, which most commonly appear in the ATP-binding pocket (encoded by exons 13/14) and/or activation loop (exons 17/18)11–15.